However, owing to a lack of understanding of the etiology and mechanisms of ILD induced by immune checkpoint inhibitors (32), further research is required on the mode of action and potential risks for the use of mTOR inhibitors subsequent to immune checkpoint inhibitors. This evidence concerns the gene MTOR and interstitial lung disease.